KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Non-cash Items (2016 - 2025)

CRISPR Therapeutics AG (CRSP) has disclosed Non-cash Items for 11 consecutive years, with $42.3 million as the latest value for Q4 2025.

  • Quarterly Non-cash Items rose 200.85% to $42.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $42.3 million through Dec 2025, up 200.85% year-over-year, with the annual reading at $42.3 million for FY2025, 771.22% up from the prior year.
  • Non-cash Items hit $42.3 million in Q4 2025 for CRISPR Therapeutics AG, up from $4.6 million in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $219.1 million in Q4 2021 to a low of $4.0 million in Q1 2021.
  • Historically, Non-cash Items has averaged $50.9 million across 5 years, with a median of $9.5 million in 2024.
  • Biggest five-year swings in Non-cash Items: plummeted 97.99% in 2021 and later soared 3345.34% in 2022.
  • Year by year, Non-cash Items stood at $219.1 million in 2021, then crashed by 85.34% to $32.1 million in 2022, then skyrocketed by 260.03% to $115.7 million in 2023, then crashed by 87.85% to $14.0 million in 2024, then soared by 200.85% to $42.3 million in 2025.
  • Business Quant data shows Non-cash Items for CRSP at $42.3 million in Q4 2025, $4.6 million in Q3 2025, and $5.0 million in Q2 2025.